Sign inJoin waitlistJoin the waitlist

Deborah M. Stephens

Physician Leader of the Hematology Clinical Trials Division · Huntsman Cancer Institute

Credentials: · · · · · · · ·

History

Spencer Fox Eccles School of Medicine
2014–Present

The Ohio State University Medical Center
The Ohio State University Medical Center
Cleveland Clinic
The Ohio State University
Kansas City University of Medicine
2007
The Ohio State University Medical Center
The University of Iowa

Research

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2016 · 761 citations
PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
Blood · 2017 · 206 citations
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study
The Lancet · 2023 · 179 citations

JB
John Byrd
36 papers
Jennifer Woyach
23 papers
Mazyar Shadman
20 papers
AD
Alexey Danilov
19 papers
Lindsey Fitzgerald
19 papers · 13 as a resident
Brian Hill
18 papers
Jennifer Brown
17 papers
Shuo Ma
17 papers
Harsh Shah
16 papers
Danielle Brander
15 papers
Geoffrey Shouse
14 papers
Reem Karmali
14 papers

Grants

Curing Through Collaboration: Utilizing Cooperative Groups in the Fight Against Chronic Lymphocytic Leukemia and B-Cell Lymphomas
National Cancer Institute · R50
Contact PI · $673.2K · Univ of North Carolina Chapel Hill
2023–2028
Novel Strategies to Eliminate Resistance to B-Cell Receptor Inhibitor Therapy in Lymphoid Malignancies
National Cancer Institute · K23
Contact PI · $901.8K · Utah State Higher Education System--University of Utah
2016–2022

Clinical trials

Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors
Principal investigator · Not yet recruiting · Phase 2
UNC Lineberger Comprehensive Cancer Center
2026–2032
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Principal investigator · Recruiting · Phase 3
National Cancer Institute (NCI)
2021–2028
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Site PI · Recruiting · Phase 2
Christine Ryan
2024–2033